Problem
The antibiotic pipeline is failing, not because drugs cannot bind their target, but because most never get inside the bacterial cell
“We estimate that by 2050, 10 million lives a year ... are at risk due to the rise of drug resistant infections”
- HM Government and Wellcome Trust
The antibiotic pipeline is failing, not because drugs cannot bind their target, but because most never get inside the bacterial cell
Neither method informs how changes to molecules affect entry and retention within bacteria, a property called accumulation.
Quantify Accumulation at Each Iteration of Your Molecule
Accumulation Prediction and Improved Molecular Design
| Benefit | User | Customer |
|---|---|---|
| New optimisation metric beyond binding affinity | More rational design | Lower compound attrition rates Faster pipeline progression |
| Remove non-accumulating compounds from screening campaigns | Reduced workload | Reduced experimental expenditure |
| Work with failing / failed candidates | Generate mechanistic insight into failing / failed candidates | Recoup prior investment on abandoned drug candidates |
“At Bilayer we are not just building software, we aim to save lives by accelerating the antibiotics pipeline.”
- CEO & CTO, Bilayer
